胸膜间皮瘤:外科医生还在吗?
恶性胸膜间皮瘤(MPM)侵袭性强、预后差,临床与病理分期常不一致,治疗选择困难。本文回顾外科在MPM中的作用,讨论 macroscopic complete resection 的适应证及术式(保留肺的胸膜切除/剥脱术与胸膜外全肺切除),强调外科仍占一席之地。
要点
- MPM临床与病理分期差异大,影响预后判断和治疗分配。
- 手术可 macroscopic complete 切除肿瘤,但部分观点认为并发症和死亡率高。
- 最佳长期结局来自手术联合其他模式的系列报告。
核心结论
- 手术仍是MPM治疗争议点,但可 macroscopic complete 切除相对耐药肿瘤,并与其它有限疗效治疗序贯联合。
- 最佳长期结局来自手术联合其他模式的系列报告,但部分社区认为手术并发症和死亡率相对有限生存期过高。
研究设计与样本
- 本文为综述,回顾MPM外科适应证及 macroscopic complete 切除的术式。
主要发现
- MPM组织学、生物学和分期知识增加,但临床与病理分期仍存在显著差异,预后和治疗结局难以预测。
- 80年代末消极期后,学术中心主导评估不同治疗方案,当时选择仅基于组织学和分期。
- 因选择标准和定义差异大,数据解读困难,至今专家间对最佳治疗无共识。
- 手术可 macroscopic complete 消除相对耐药的肿瘤,为其他有限疗效治疗提供序贯机会。
关键数值与推荐
- 手术适应证包括 macroscopic complete 切除,术式有保留肺的(扩大)胸膜切除/剥脱术和胸膜外全肺切除。
临床怎么用
- MPM治疗需个性化,手术应权衡并发症和死亡率与有限生存期,并与其他模式序贯联合。
局限性
- 原文未报告系统检索范围、样本量或具体数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Malignant pleural mesothelioma (MPM) is a rare malignancy with some unique characteristics. Tumor biology is aggressive and prognosis is poor. Despite more knowledge on histology, tumor biology and staging, there is still a relevant discrepancy between clinical and pathologic staging resulting in difficult prediction of prognosis and treatment outcome, making treatment allocation more challenging than in most other malignancies. After years of nihilism in the late 80s, a period of activism started evaluating different treatment protocols combined with research driven mainly by academic centers; at the time, selection was based on histology and stage only. This period was important to gain knowledge about the disease. However, the interpretation of data was difficult since selection criteria and definitions varied substantially. Not surprisingly, until now there is no common agreement on best treatment even among specialists. Hence, a review of our current concepts is indicated and personalized treatment should become applicable in the future. Surgery was and still is an issue of debate. In principle, surgery is an effective approach as it allows macroscopic complete elimination of a tumor, which is relatively resistant to medical treatment. It helps to set the clock back and other therapies that have also just a limited effect can be applied sequentially before or after surgery. Furthermore, to date best long-term outcome is reported from surgical series in combination with other modalities. However, part of the community considers surgery associated with too high morbidity and mortality when balanced to the limited life expectancy. This criticism is understandable, since poor results after surgery are reported. The present article will review the indication for surgery and discuss the different procedures available for macroscopic complete resection-such as lung-preserving (extended) pleurectomy/decortication as well as extrapleural pneumonectomy to illustrate that 'The surgeon is still there!'
引用
- Opitz I, Weder W. Pleural mesothelioma: is the surgeon still there? Ann Oncol. 2018. PMID: 29905765. doi:10.1093/annonc/mdy195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。